When Orlando Health launched a $20-million venture capital arm in 2018, it had several goals in mind. The first was generating a financial return for the health care system by investing in companies whose products and services would elevate the level of care it delivers. A secondary objective, says Erick Hawkins, Orlando Health’s senior vice president of strategic management, was “creating a culture of innovation throughout the enterprise.” Four years later, he says, the strategy is paying dividends on both fronts.

This story also features: Gauss Surgical; Emergo Therapeutics; BioStable Science & Engineering; Phynd Technologies; Tampa General; TGH InnoVentures; Rachel Feinman

 

Want to read the whole article?
Select from the following options: